<DOC>
	<DOCNO>NCT01934582</DOCNO>
	<brief_summary>A sub-study TDE-PH-304 protocol ass pharmacokinetics patient transition twice daily dose regimen oral treprostinil three time daily dose regimen .</brief_summary>
	<brief_title>A Pharmacokinetic Substudy TDE-PH-304 Protocol</brief_title>
	<detailed_description>As note `` Brief Summary '' .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>1 ) Only subject eligible enter Protocol TDEPH304 may participate substudy . 1 . The subject must voluntarily give informed consent participate substudy . 2 . No dose change study drug make within 5 day pharmacokinetic ( PK ) substudy visit . 3 . No addition deletion concurrent medication make within 7 day pharmacokinetic substudy visit . Note : change diuretic and/or anticoagulant permit . 4 . The precede evening dose study drug take 9 13 hour prior BID dose 610 hour prior TID morning dose study drug ensure trough level study drug PK sampling . 5 . Subject dose study drug day PK sampling must observe clinic study personnel . 6 . Subject experienced significant loss blood ( &gt; 450 mL ) within last 6 week pharmacokinetic substudy visit . 7 . The subject must receive CYP 2C8 inducer inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>